TABLE 3.
The information of 13 IRGs related diseases and functions.
| IRGs | Disease type | Functions |
| AQP9 | Astrocytoma (Lv et al., 2018), hepatocellular carcinoma (Liao et al., 2020), breast cancer (Zhu et al., 2019), renal cell carcinoma (Yamada et al., 2019), melanoma (Gao et al., 2011) colorectal cancer and gastric cancer (Huang et al., 2017; Thapa et al., 2018) | Promote the invasion and motility inhibit cell apoptosis Overexpression of AQP9 were correlated to have better OS |
| LMBR1L | In mice (Choi et al., 2019) | Mutant LMBR1L impaired the development of lymphoid lineages |
| FGF20 | Human hepatocellular carcinoma cells (Wang et al., 2017) | Stimulate the proliferation and migration of cancer cells |
| TANK | Antiviral innate immunity and negatively regulates NF-NF-κB signaling pathway (Kadkhodazadeh et al., 2012; Song et al., 2012). | |
| CRP | BLBCL (Cao et al., 2012; Wang et al., 2016), breast cancer, non-metastatic clear cell renal cell carcinoma, non-small cell lung cancer and colorectal cancer risk (Nimptsch et al., 2015; Hu et al., 2016; Akamine et al., 2018; Preet et al., 2018a, b) | Inflammatory marker |
| ORM1 | Rat model of septic stroke pathology | Neuroinflammation (Astrup et al., 2019; Higuchi et al., 2020; Mcguckin et al., 2020; Sharma et al., 2020) |
| JAK1 | Immune deficiency in natural killer cells (Witalisz et al., 2019), the mutation of JAK1 was related to immune escape in many cancers (Xie et al., 2009; Albacker et al., 2017) apoptosis and growth in several cancers (Siavash et al., 2004) optimal fitness of activated B cell (Zhu et al., 2017) | |
| BACH1 | Lung cancer (Wiel et al., 2019), epithelial ovarian cancer, colon cancer, prostate cancer and colorectal cancer (Davudian et al., 2016; Shajari et al., 2017; Zhu et al., 2018; Han et al., 2019) | Stimulates glycolysis dependent lung cancer metastasis required for metastatic AsPC-1 cells (Sato et al., 2020) stimulate cancer cell metastasis |
| IFITM1 | Lung cancer, colorectal cancer, inflammatory breast cancer, cervical squamous cell carcinoma and lung cancer (FangYu et al., 2015; Ogony et al., 2016; Jin et al., 2017; Zheng et al., 2017; Yan et al., 2019) | Silenced IFITM1 caused inhibited migration and invasion |
| TNFSF10 | Amyloid-related disorders (Cantarella et al., 2015) | Stimulated proliferation and inflammation, and inhibited apoptosis (Huang et al., 2019) improvement and restrained immune/inflammatory response |
| FGF12 | Esophageal squamous cell carcinoma (Bhushan et al., 2017a) | Silencing FGF12 inhibited apoptosis of radiation-induced cell and the cell migration and proliferation (Fumiaki et al., 2008; Bhushan et al., 2017b) |
| RFX5 | Hepatocellular carcinoma | Promoted the progression of the cell cycle (Chen et al., 2020) |
| LAP3 | Glioma cells (He et al., 2015), esophageal squamous cell (Zhang et al., 2014), ovarian carcinoma (Suganuma et al., 2005; Wang et al., 2015) breast cancer (Wang et al., 2020) and hepatocellular carcinoma (Tian et al., 2014) | Regulate cell proliferation, invasion and/or angiogenesis expressed in several malignant and affects tumor angiogenesis |